Bernstein Initiates Coverage On Gilead Sciences with Outperform Rating, Announces Price Target of $105
Portfolio Pulse from Benzinga Newsdesk
Bernstein analyst Aaron Gal has initiated coverage on Gilead Sciences with an Outperform rating and set a price target of $105.
October 17, 2024 | 11:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bernstein has initiated coverage on Gilead Sciences with an Outperform rating and a price target of $105, indicating a positive outlook.
The initiation of coverage with an Outperform rating and a price target of $105 by Bernstein suggests a positive sentiment towards Gilead Sciences. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100